Industry veteran Abbas Hussain named chairman of Asceneuron

Switzerland-based Asceneuron has announced the appointment of Abbas Hussain as its new chairman of to its board of directors.

Privately-held Asceneuron was created n 2012 as a spin-out of Merck KGaA’s (MRK: DE) Merck Serono division, with the aim of developing therapies for the treatment of Alzheimer's disease and Tau protein-related pathologies, by advancing Merck Serono's pre-clinical programs targeting these conditions towards clinical testing as rapidly as possible.

Mr Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe. He has a strong track record across the pharmaceutical value chain in both mature and emerging markets.